1.Research progress on the intervention of sarcopenia with traditional Chinese medicine based on the AMPK signaling pathway
Wenyu FAN ; Bairong HUANG ; Congmin HONG ; Yan CHEN ; Jiayin WANG ; Jing GAO ; Xiaodong FENG
China Pharmacy 2026;37(9):1229-1235
arcopenia is a systemic skeletal muscle disorder characterized by a decrease in skeletal muscle mass and progressive decline in function, with multiple signaling pathways involved in its occurrence and development. Among them, the AMP-activated protein kinase (AMPK) signaling pathway, as a key pathway regulating cellular energy homeostasis, plays an important role in the regulation of skeletal muscle metabolism and functional maintenance by improving abnormalities in glucose and lipid metabolism, balancing skeletal muscle protein synthesis and degradation, improving mitochondrial function, promoting autophagy, and inhibiting inflammatory responses and oxidative stress. This article reviews the research progress on how various traditional Chinese medicine (TCM) monomers, including polyphenols, flavonoids, and terpenoids; various traditional Chinese medicine extracts, such as those from Lycium barbarum , Asini Corii Colla, and Panax quinquefolium , and TCM compounds, such as Guiqi zhuangjin decoction, Jianpi qiangji granules, and Qigu capsules, intervene in sarcopenia by regulating the AMPK signaling pathway to promote muscle protein synthesis, inhibit protein degradation, improve mitochondrial function, and alleviate inflammation and oxidative stress. Additionally, their molecular mechanisms are explored. The aim is to deeply elucidate the basis of TCM in the prevention and treatment of sarcopenia and to provide theoretical support for the development of related innovative drugs.
2.Herbal Textual Research on Inulae Flos in Famous Classical Formulas
Caixia LIU ; Yue HAN ; Yanzhu MA ; Lei GAO ; Sheng WANG ; Yan YANG ; Wenchuan LUO ; Ling JIN ; Jing SHAO ; Zhijia CUI ; Zhilai ZHAN
Chinese Journal of Experimental Traditional Medical Formulae 2026;32(3):210-221
In this paper, by referring to ancient and modern literature, the textual research of Inulae Flos has been conducted to clarify the name, origin, production area, quality evaluation, harvesting, processing and others, so as to provide reference and basis for the development and utilization of famous classical formulas containing this herb. After textual research, it could be verified that the medicinal use of Inulae Flos was first recorded in Shennong Bencaojing of the Han dynasty. In successive dynasties, Xuanfuhua has been taken as the official name, and it also has other alternative names such as Jinfeicao, Daogeng and Jinqianhua. The period before the Song and Yuan dynasties, the main origin of Inulae Flos was the Asteraceae plant Inula japonica, and from the Ming and Qing dynasties to the present, I. japonica and I. britannica are the primary source. In addition to the dominant basal species, there are also regional species such as I. linariifolia, I. helianthus-aquatili, and I. hupehensis. The earliest recorded production areas in ancient times were Henan, Hubei and other places, and the literature records that it has been distributed throughout the country since modern times. The medicinal part is its flower, the harvesting and processing method recorded in the past dynasties is mainly harvested in the fifth and ninth lunar months, and dried in the sun, and the modern harvesting is mostly harvested in summer and autumn when the flowers bloom, in order to remove impurities, dry in the shade or dry in the sun. In addition, the roots, whole herbs and aerial parts are used as medicinal materials. In ancient times, there were no records about the quality of Inulae Flos, and in modern times, it is generally believed that the quality of complete flower structure, small receptacles, large blooms, yellow petals, long filaments, many fluffs, no fragments, and no branches is better. Ancient processing methods primarily involved cleaning, steaming, and sun-drying, supplemented by techniques such as boiling, roasting, burning, simmering, stir-frying, and honey-processing. Modern processing focuses mainly on cleaning the stems and leaves before use. Regarding the medicinal properties, ancient texts describe it as salty and sweet in taste, slightly warm in nature, and mildly toxic. Modern studies characterize it as bitter, pungent, and salty in taste, with a slightly warm nature. Its therapeutic effects remain consistent across eras, including descending Qi, resolving phlegm, promoting diuresis, and stopping vomiting. Based on the research results, it is recommended that when developing famous classical formulas containing Inulae Flos, either I. japonica or I. britannica should be used as the medicinal source. Processing methods should follow formula requirements, where no processing instructions are specified, the raw products may be used after cleaning.
3.Herbal Textual Research on Inulae Flos in Famous Classical Formulas
Caixia LIU ; Yue HAN ; Yanzhu MA ; Lei GAO ; Sheng WANG ; Yan YANG ; Wenchuan LUO ; Ling JIN ; Jing SHAO ; Zhijia CUI ; Zhilai ZHAN
Chinese Journal of Experimental Traditional Medical Formulae 2026;32(3):210-221
In this paper, by referring to ancient and modern literature, the textual research of Inulae Flos has been conducted to clarify the name, origin, production area, quality evaluation, harvesting, processing and others, so as to provide reference and basis for the development and utilization of famous classical formulas containing this herb. After textual research, it could be verified that the medicinal use of Inulae Flos was first recorded in Shennong Bencaojing of the Han dynasty. In successive dynasties, Xuanfuhua has been taken as the official name, and it also has other alternative names such as Jinfeicao, Daogeng and Jinqianhua. The period before the Song and Yuan dynasties, the main origin of Inulae Flos was the Asteraceae plant Inula japonica, and from the Ming and Qing dynasties to the present, I. japonica and I. britannica are the primary source. In addition to the dominant basal species, there are also regional species such as I. linariifolia, I. helianthus-aquatili, and I. hupehensis. The earliest recorded production areas in ancient times were Henan, Hubei and other places, and the literature records that it has been distributed throughout the country since modern times. The medicinal part is its flower, the harvesting and processing method recorded in the past dynasties is mainly harvested in the fifth and ninth lunar months, and dried in the sun, and the modern harvesting is mostly harvested in summer and autumn when the flowers bloom, in order to remove impurities, dry in the shade or dry in the sun. In addition, the roots, whole herbs and aerial parts are used as medicinal materials. In ancient times, there were no records about the quality of Inulae Flos, and in modern times, it is generally believed that the quality of complete flower structure, small receptacles, large blooms, yellow petals, long filaments, many fluffs, no fragments, and no branches is better. Ancient processing methods primarily involved cleaning, steaming, and sun-drying, supplemented by techniques such as boiling, roasting, burning, simmering, stir-frying, and honey-processing. Modern processing focuses mainly on cleaning the stems and leaves before use. Regarding the medicinal properties, ancient texts describe it as salty and sweet in taste, slightly warm in nature, and mildly toxic. Modern studies characterize it as bitter, pungent, and salty in taste, with a slightly warm nature. Its therapeutic effects remain consistent across eras, including descending Qi, resolving phlegm, promoting diuresis, and stopping vomiting. Based on the research results, it is recommended that when developing famous classical formulas containing Inulae Flos, either I. japonica or I. britannica should be used as the medicinal source. Processing methods should follow formula requirements, where no processing instructions are specified, the raw products may be used after cleaning.
4.Mechanistic Insights into The Role of LEPROTs and COPI Retrograde Transport in Regulating Golgi Morphology
Jing-Hu GAO ; Lin-Yue ZHAO ; Yu-Lu ZHANG ; Yan-Fang WU ; Bing YAN
Progress in Biochemistry and Biophysics 2026;53(6):1746-1757
ObjectiveThe Golgi apparatus serves as a central hub in the eukaryotic secretory pathway, responsible for the processing, sorting, and trafficking of proteins and lipids. In mammalian cells, the Golgi typically forms a perinuclear ribbon-like structure composed of laterally connected cisternae stacks.The maintenance of Golgi ribbon structure depends on the balance of membrane flux across multiple intracellular trafficking pathways, yet the specific contributions of distinct trafficking branches to Golgi macroscopic morphology remain elusive. In mammalian cells, the Golgi ribbon is typically organized as a perinuclear, laterally connected structure composed of stacked cisternae, and its integrity is highly dynamic and sensitive to perturbations in membrane trafficking. This study aims to elucidate the role of coat protein complex I (COPI)-mediated retrograde transport in maintaining the Golgi ribbon and to dissect the functional relationship between the transmembrane cargo receptors LEPROT/LEPROTL1 (LEPROTs) and the COPI adaptor GOLPH3. MethodsUsing siRNA interference and gene-deficient cell lines, we selectively perturbed COPI- or adaptor protein complex 1 (AP-1)-mediated trafficking pathways in HeLa cells. To quantitatively evaluate Golgi morphology, we employed a “Golgi Angle”-based measurement to assess its circumferential distribution around the nucleus. The spatial distribution of the Golgi ribbon was quantitatively analyzed using confocal microscopy, while Golgi ultrastructure and vesicle density were examined via transmission electron microscopy. Additionally, the subcellular distribution of COPI components was assessed by immunofluorescence co-localization. ResultsSelective inhibition of COPI retrograde transport significantly induced the circumferential extension of the Golgi ribbon around the nucleus, whereas blocking AP-1-mediated anterograde transport resulted in Golgi compaction, indicating opposing roles. These results suggest that different trafficking branches downstream of ARF1 exert distinct and even antagonistic effects on Golgi morphology. LEPROTs-deficient cells exhibited a Golgi extension phenotype highly consistent with COPI impairment. Furthermore, knockdown of GOLPH3 in a LEPROTs double-knockout background produced a significant additive effect on Golgi extension, suggesting that LEPROTs and GOLPH3 play non-redundant roles in regulating COPI-related trafficking processes. Mechanistically, loss of either LEPROTs or GOLPH3 led to the aberrant accumulation of COPI components at endoplasmic reticulum exit sites, accompanied by a reduction in COPI-like vesicles around the Golgi. This redistribution indicates a defect in COPI recycling between the ER-Golgi interface and the Golgi apparatus. Ultrastructural analysis revealed that Golgi cisternae in defective cells became shorter and thicker while maintaining a stable number of stacks. In parallel, the density of Golgi-associated vesicles was markedly decreased, further supporting an impairment in COPI vesicle formation or budding processes. ConclusionThis study demonstrates that active COPI retrograde transport is a critical factor in restricting the over-connection of the Golgi ribbon and maintaining its compactness. Rather than causing fragmentation, partial disruption of COPI function leads to a distinct morphological outcome characterized by Golgi ribbon extension at the light microscopy level and cisternal remodeling at the ultrastructural level. LEPROTs and GOLPH3 cooperatively promote the recycling and vesiculation of COPI components, thereby imposing a structural constraint on the Golgi periphery. Our findings support a model in which multiple adaptor proteins act in parallel to sustain efficient COPI cycling, thereby maintaining Golgi structural homeostasis. These findings provide new cell biological evidence for the membrane trafficking basis of Golgi morphological homeostasis.
5.Expert consensus on the application of artificial intelligence in lung cancer screening, diagnosis, and treatment (2026 edition)
Wenzhao ZHONG ; Haibo WANG ; Yi HU ; Hao ZHANG ; Jigang DAI ; Junqiang FAN ; Guibin QIAO ; Fan YANG ; Jian HU ; Fengwei TAN ; Xuening YANG ; Qiang PU ; Zihao CHEN ; Hongxia TIAN ; Lunxu LIU ; Hecheng LI ; Xiaolong YAN ; Zongyang YU ; Zhenbin QIU ; Yihua SUN ; Jing HU ; Yuhang SHI ; Zhifei GUO ; Peng ZHANG ; Kezhong CHEN ; Shugeng GAO ; Yilong WU
Chinese Journal of Clinical Thoracic and Cardiovascular Surgery 2026;33(06):848-856
With the continuous deepening of the concept of precision diagnosis and treatment for lung cancer, how to achieve higher efficiency and accuracy in the screening, diagnosis, and treatment pathways in clinical practice has become an important issue that urgently needs to be overcome. The current clinical difficulty lies in the fact that despite continuous advancements in imaging and molecular diagnostic technologies, there are still limitations in manual efficiency and subjective experience when it comes to massive data analysis and multi-scale feature extraction. Artificial intelligence (AI), especially algorithm systems based on deep learning, is an innovative technology capable of deeply empowering medical big data. This method utilizes algorithms such as convolutional neural networks, combined with radiomics, pathomics, and multi-modal data fusion analysis, demonstrating immense potential in early precise detection and benign-malignant differentiation of pulmonary nodules, digital pathological subtype recognition and non-invasive prediction of driver genes, precise 3D surgical planning and automatic delineation of radiotherapy target volumes, as well as dynamic risk warning during follow-up. This innovative technology provides a brand-new solution for realizing intelligent and individualized lung cancer diagnosis and treatment models. This consensus, based on the latest evidence from evidence-based medicine and combined with the development trends in the AI field and real-world clinical needs, was ultimately formed by gathering the consensus opinions of multidisciplinary experts in radiology, pathology, thoracic surgery, and other fields. The main content covers the application specifications of AI in the three core scenarios of lung cancer screening, diagnosis, and treatment, the technical standards for data collection and algorithm validation, as well as the ethical and regulatory challenges faced at the current stage. It aims to clarify the applicable boundaries of AI as a clinical auxiliary decision support tool, providing scientific guidance and standardized exploration directions for peers currently engaged in or planning to carry out AI-assisted clinical diagnosis, treatment, and translation of lung cancer.
6.Graphene-mediated Far-infrared Therapy Enhances Anti-non-small Cell Lung Cancer Effects of Panax quinquefolium Saponins via cGAS/STING Signaling Pathway
Huifang ZANG ; Zikai GENG ; Yan GAO ; Lu LIU ; Yifei WANG ; Bonian ZHAO ; Jing LYU
Chinese Journal of Experimental Traditional Medical Formulae 2026;32(21):131-145
ObjectiveTo investigate whether the inhibitory effect of Panax quinquefolium saponins (PQS) on non-small cell lung cancer (NSCLC) is enhanced under graphene-mediated far-infrared therapy (GFIR), and to analyze its relationships with mitochondrial dysfunction, mitochondrial DNA (mtDNA) leakage, and the activation of cyclic GMP-AMP synthase (cGAS)/stimulator of interferon genes (STING) signaling pathways. MethodsIn the cell experiments, the cell-counting kit 8 (CCK-8) was employed to assess the inhibitory effects of PQS alone or in combination with GFIR (PQS+GFIR) on A549 cell viability. The scratch assay and the colony formation assay were adopted to evaluate cell migration and colony formation capabilities, respectively. Flow cytometry was employed to assess apoptosis, mitochondrial membrane potential, and reactive oxygen species (ROS) levels. Immunofluorescence (IF) assay was performed to assess mitochondrial localization. Real-time polymerase China reaction(PCR) was used to detect mitochondrial DNA (mtDNA) leakage. A STING knockdown cell model was established by transfecting cells with small interfering RNA (siRNA), and the knockdown efficiency was assessed by Real-time PCR and Western blot. The cell viability and apoptosis following gene knockdown were assessed through the CCK-8 assay and flow cytometry. In the animal experiments, an allogeneic xenograft mouse model was established with Lewis lung cancer cells. Mice were randomized into a control group, a model group, a cisplatin group, a low-dose PQS (PQS-Low, 90 mg·kg-1) group, a high-dose PQS (PQS-High, 180 mg·kg-1) group, a low-dose PQS combined with GFIR (PQS-Low+GFIR, 90 mg·kg-1) group, and a high-dose PQS combined with GFIR (PQS-High+GFIR, 180 mg·kg-1) group. Treatment lasted for 14 days, and the fluorescence intensity was monitored at the tumor site by small-animal in vivo imaging during the treatment period. Flow cytometry was utilized to determine the proportions of T-lymphocyte subsets, B-lymphocyte levels, and peripheral blood NK cell levels in the spleens of mice. Immunohistochemical (IHC) staining was performed to assess the infiltration of CD3+, CD4+, and CD8+ T-lymphocytes in the tumor tissue. Enzyme-linked immunosorbent assay (ELISA) was conducted to measure the levels of interferon-α (IFN-α), interferon-β (IFN-β), tumor necrosis factor-α (TNF-α), and interleukin-6 (IL-6) in mouse tumors. The mRNA levels of cGAS, STING, TANK-binding kinase 1 (TBK1), interferon regulatory factor 3 (IRF3), interferon beta 1 (IFNB1), and nuclear factor κB p65 (NF-κB p65) were determined by Real-time PCR. The protein levels of cGAS, STING, p-STING, TBK1, p-TBK1, IRF3, p-IRF3, NF-κB p65, and p-NF-κB p65 were quantified via Western blot. ResultsThe cell experiment results showed that compared with the control group, PQS inhibited the viability and migration of A549 cells, promoted apoptosis, affected mitochondrial localization, reduced mitochondrial membrane potential, increased the ROS level, and promoted mtDNA leakage. Following STING knockdown, the reductions in cell viability and the apoptosis-inducing effects caused by PQS were partially reversed (P<0.05, P<0.01). Compared with the PQS group, the PQS+GFIR group showed inhibited A549 cell migration and colony formation, exacerbated apoptosis, downregulated mitochondrial membrane potential, elevated ROS levels, and promoted mtDNA leakage. After STING knockdown, the reduced A549 cell viability and abnormal apoptosis phenotype were further reversed (P<0.05, P<0.01). The animal experiment results showed that compared with the control group, the model group mice exhibited reduced proportions of T-lymphocyte subsets, CD19+ B-lymphocyte levels, and peripheral blood NK1.1+ cell levels in the spleen (P<0.01). Compared with the model group, the PQS group showed increased immune cell parameters in mice (P<0.05, P<0.01). Compared with the PQS group, the PQS+GFIR group exhibited enhanced levels of the aforementioned indicators (P<0.01). Compared with the model group, the PQS group showed significantly reduced fluorescence intensity in transplanted tumors, significantly upregulated expression of CD3 and CD4 in the tumor tissue, elevated levels of IFN-α and IL-6 in tumors, and upregulated mRNA levels of cGAS, STING, TBK1, IRF3, IFNB1, and NF-κB p65 as well as upregulated protein level of cGAS and phosphorylation level of STING in tumors (P<0.05, P<0.01). Compared with the PQS group, the PQS+GFIR group demonstrated further reduced tumor fluorescence intensity, elevated levels of CD3, CD4, and CD8 as well as cytokine levels in tumor tissue, and upregulated mRNA levels of genes related to the cGAS/STING pathway as well as upregulated protein level of cGAS and phosphorylation levels of STING, TBK1, IRF3, and NF-κB p65 (P<0.05, P<0.01) ConclusionGFIR enhances the inhibitory effect of PQS on NSCLC, potentially through mitochondrial dysfunction, mtDNA leakage, and activation of the cGAS/STING signaling pathway.
7.Graphene-mediated Far-infrared Therapy Enhances Anti-non-small Cell Lung Cancer Effects of Panax quinquefolium Saponins via cGAS/STING Signaling Pathway
Huifang ZANG ; Zikai GENG ; Yan GAO ; Lu LIU ; Yifei WANG ; Bonian ZHAO ; Jing LYU
Chinese Journal of Experimental Traditional Medical Formulae 2026;32(21):131-145
ObjectiveTo investigate whether the inhibitory effect of Panax quinquefolium saponins (PQS) on non-small cell lung cancer (NSCLC) is enhanced under graphene-mediated far-infrared therapy (GFIR), and to analyze its relationships with mitochondrial dysfunction, mitochondrial DNA (mtDNA) leakage, and the activation of cyclic GMP-AMP synthase (cGAS)/stimulator of interferon genes (STING) signaling pathways. MethodsIn the cell experiments, the cell-counting kit 8 (CCK-8) was employed to assess the inhibitory effects of PQS alone or in combination with GFIR (PQS+GFIR) on A549 cell viability. The scratch assay and the colony formation assay were adopted to evaluate cell migration and colony formation capabilities, respectively. Flow cytometry was employed to assess apoptosis, mitochondrial membrane potential, and reactive oxygen species (ROS) levels. Immunofluorescence (IF) assay was performed to assess mitochondrial localization. Real-time polymerase China reaction(PCR) was used to detect mitochondrial DNA (mtDNA) leakage. A STING knockdown cell model was established by transfecting cells with small interfering RNA (siRNA), and the knockdown efficiency was assessed by Real-time PCR and Western blot. The cell viability and apoptosis following gene knockdown were assessed through the CCK-8 assay and flow cytometry. In the animal experiments, an allogeneic xenograft mouse model was established with Lewis lung cancer cells. Mice were randomized into a control group, a model group, a cisplatin group, a low-dose PQS (PQS-Low, 90 mg·kg-1) group, a high-dose PQS (PQS-High, 180 mg·kg-1) group, a low-dose PQS combined with GFIR (PQS-Low+GFIR, 90 mg·kg-1) group, and a high-dose PQS combined with GFIR (PQS-High+GFIR, 180 mg·kg-1) group. Treatment lasted for 14 days, and the fluorescence intensity was monitored at the tumor site by small-animal in vivo imaging during the treatment period. Flow cytometry was utilized to determine the proportions of T-lymphocyte subsets, B-lymphocyte levels, and peripheral blood NK cell levels in the spleens of mice. Immunohistochemical (IHC) staining was performed to assess the infiltration of CD3+, CD4+, and CD8+ T-lymphocytes in the tumor tissue. Enzyme-linked immunosorbent assay (ELISA) was conducted to measure the levels of interferon-α (IFN-α), interferon-β (IFN-β), tumor necrosis factor-α (TNF-α), and interleukin-6 (IL-6) in mouse tumors. The mRNA levels of cGAS, STING, TANK-binding kinase 1 (TBK1), interferon regulatory factor 3 (IRF3), interferon beta 1 (IFNB1), and nuclear factor κB p65 (NF-κB p65) were determined by Real-time PCR. The protein levels of cGAS, STING, p-STING, TBK1, p-TBK1, IRF3, p-IRF3, NF-κB p65, and p-NF-κB p65 were quantified via Western blot. ResultsThe cell experiment results showed that compared with the control group, PQS inhibited the viability and migration of A549 cells, promoted apoptosis, affected mitochondrial localization, reduced mitochondrial membrane potential, increased the ROS level, and promoted mtDNA leakage. Following STING knockdown, the reductions in cell viability and the apoptosis-inducing effects caused by PQS were partially reversed (P<0.05, P<0.01). Compared with the PQS group, the PQS+GFIR group showed inhibited A549 cell migration and colony formation, exacerbated apoptosis, downregulated mitochondrial membrane potential, elevated ROS levels, and promoted mtDNA leakage. After STING knockdown, the reduced A549 cell viability and abnormal apoptosis phenotype were further reversed (P<0.05, P<0.01). The animal experiment results showed that compared with the control group, the model group mice exhibited reduced proportions of T-lymphocyte subsets, CD19+ B-lymphocyte levels, and peripheral blood NK1.1+ cell levels in the spleen (P<0.01). Compared with the model group, the PQS group showed increased immune cell parameters in mice (P<0.05, P<0.01). Compared with the PQS group, the PQS+GFIR group exhibited enhanced levels of the aforementioned indicators (P<0.01). Compared with the model group, the PQS group showed significantly reduced fluorescence intensity in transplanted tumors, significantly upregulated expression of CD3 and CD4 in the tumor tissue, elevated levels of IFN-α and IL-6 in tumors, and upregulated mRNA levels of cGAS, STING, TBK1, IRF3, IFNB1, and NF-κB p65 as well as upregulated protein level of cGAS and phosphorylation level of STING in tumors (P<0.05, P<0.01). Compared with the PQS group, the PQS+GFIR group demonstrated further reduced tumor fluorescence intensity, elevated levels of CD3, CD4, and CD8 as well as cytokine levels in tumor tissue, and upregulated mRNA levels of genes related to the cGAS/STING pathway as well as upregulated protein level of cGAS and phosphorylation levels of STING, TBK1, IRF3, and NF-κB p65 (P<0.05, P<0.01) ConclusionGFIR enhances the inhibitory effect of PQS on NSCLC, potentially through mitochondrial dysfunction, mtDNA leakage, and activation of the cGAS/STING signaling pathway.
8.Chinese expert consensus on the clinical application of recombinant human thyroid-stimulating hormone (2025 edition)
Chentian SHEN ; Yushen GU ; Hui TAN ; Anren KUANG ; Sijin LI ; Yaming LI ; Jing WANG ; Ningyi JIANG ; Jian TAN ; Zhuoying WANG ; Shaoyan LIU ; Xiaoyi LI ; Jugao FANG ; Dingcun LUO ; Youben FAN ; Hui WANG ; Yuetao WANG ; Xuemei WANG ; Feng WANG ; Wei FU ; Feng SHI ; Xuegong LIU ; Zhongwei LÜ ; Yan XING ; Lin LI ; Hui YANG ; Jun XIN ; Yifan ZHANG ; Yue CHEN ; Yansong LIN ; Wei OUYANG ; Shuzhan YAO ; Changjiu ZHAO ; Xinming ZHAO ; Zairong GAO ; Dingde HUANG ; Qiang WEN ; Xingmin HAN ; Cen LOU ; Weibing MIAO ; Wei FAN ; Quanyong LUO ; Hongcheng SHI
Chinese Journal of Clinical Medicine 2026;33(5):932-944
The recombinant human thyroid-stimulating hormone (rhTSH) can be used for differentiated thyroid cancer (DTC) preparation before 131I therapy, and follow-up. Since its approval by the American Food and Drug Administration (FDA) in 1998, rhTSH has been clinically used in European countries, the United States, and other countries for nearly 30 years. In April 2024, China’s first independently developed rhTSH agent was approved. Based on clinical experience and evidence from domestic and international studies, an expert consensus on the application of rhTSH has been developed following thorough consultations among experts. The consensus offers evidence-based recommendations to guide the appropriate use of rhTSH in clinical practice.
9.Expression of EZH2 in breast cancer tissue and its prognostic survival analysis
Liying CAI ; Guoxin SUN ; Lei GUO ; Yuan GAO ; Yan LIU ; Xiaochuan SUN ; Xiaohong HUANG ; Jing CHEN ; Yating ZHAO
Clinical Medicine of China 2025;41(2):116-121
Objective:To investigate the expression characteristics of Zeste enhancer of Zeste homolog 2 (EZH2) in breast cancer tissue and its influence on tumor progression and prognosis.Methods:Transcriptome data of breast cancer tissue and normal breast tissue adjacent to cancer as well as clinical data of patients were obtained from the cancer genome atlas (TCGA) database, gene expression comprehensive database and European genome phenotype archives database, and the difference of EZH2 expression was analyzed using TIMER 2.0 platform. The survival information of breast cancer patients was obtained from the Kaplan Meier Plotter database, and the overall survival time, relapse free survival time and distant metastasis free survival time of breast cancer patients with low EZH2 expression and high EZH2 expression were compared. Select 14 nude mice were selected and randomly divided into si-EZH2 group and control group, with 7 mice in each group.MCF7 culture suspensions transfected with EZH2 knockdown plasmid and control plasmid were inoculated for corresponding group. The body mass and tumor volume of two groups of nude mice inoculated with MCF7 cells were compared at different times. On the 28th day, the nude mice were euthanized and the tumors were dissected to compare the tumor mass of the two groups of nude mice. The normally distributed quantitative data was represented by xˉ ± s. Two independent sample t-tests were used for comparison between two groups, repeated measures ANOVA was used for comparison of body mass and tumor volume between two groups of nude mice at different times, and Bonferroni test was used for pairwise comparison. The comparison of survival rates was conducted using log rank test. Results:A total of 1085 breast cancer tissues and 291 normal adjacent breast tissues were included in the TCGA database. EZH2 expression in breast cancer tissues was higher than that in normal adjacent breast tissues ( P<0.05). In the Kaplan Meier Plotter database, the total survival time, relapse free survival time, and distant metastasis free survival time of breast cancer patients in the EZH2 overexpression group were shorter than those in the EZH2 low expression group ( P=0.013, <0.001, <0.001). After 7 days of inoculation with MCF7 culture suspension, significant subcutaneous tumors were observed on the left back of both groups of nude mice. On the first day, there were no statistically significant difference in body mass between the two groups of nude mice ( P>0.05); On day 7, 13, 19, 25, and 28, the body mass and tumor volume of both groups of nude mice gradually increased (nude mouse body mass: within group F=29.31, P<0.001, between groups F=234.32, P<0.001, Finteraction=16.83, P<0.001; Tumor volume: within group F=34.00, P<0.001, between groups F=193.17, P<0.001, Finteraction=35.61, P<0.001). And the body mass of the siEZH2 group nude mice was higher than that of control group (all P<0.05). On days 19, 25, and 28, tumor the volume of the siEZH2 group nude mice was smaller than that of control group (all P<0.05). On the 28th day, the mass of tumors dissected in the siEZH2 group of nude mice was lower than that in the control group [(0.30±0.07) g vs. (0.61±0.14) g, t=5.16, P<0.001]。 Conclusions:EZH2 is highly expressed in breast cancer tissues and is significantly associated with poor prognosis. Knockdown of EZH2 can significantly inhibit the proliferation and tumor formation of breast cancer cells.
10.Experimental study on the decontamination ability of different cleaning waters for surgical instruments
Bing-qing LIAO ; Xiao-mei REN ; Jing-rong WEI ; Yan GAO ; Zhong-jin YAN ; Xiao-feng LI ; Bin LI
Journal of Regional Anatomy and Operative Surgery 2025;34(7):610-613
Objective To analyze differences of purified water,softened water,and concentrated softened water on the decontamination effects for surgical instruments,so as to provide a reliable reference for the selection of cleaning water for surgical instruments.Methods The physical and chemical indexes and components of concentrated softened water,softened water,and purified water were detected,and their cleaning effects for instrument were compared.The decontamination cleaning experiment was conducted in three hospitals with different types of cleaning water using mini cleaning machines,and the differences in the decontamination time were analyzed.The cleaning and decontamination experiments on contaminated instruments was performed using a spray cleaning and disinfection device,and the cleaning effects of instruments with different types of cleaning water were analyzed.Results Calcium content and hardness of the three types of cleaning water were all at a low level,which can avoid scale adhesion for cleaning surgical instruments.There were statistically significant differences in the pH value,conductivity,and contents of calcium,sodium and chloride among the three cleaning waters(P<0.05).The purified water was weakly acidic,and its conductivity,hardness,and contents of calcium,sodium and chloride were all at low levels.The softened water and concentrated softened water were weakly alkaline,with high levels of conductivity and sodium content and low level of chloride.There were statistically significant differences in the decontamination time of the purified water,softened water and concentrated softened water among hospitals(P<0.05).Under the same contamination condition of surgical instruments,there was a statistically significant difference in the qualified rate of instruments cleaning in the upper and lower cleaning baskets with different cleaning waters(P<0.05).Conclusion Concentrated softened water and softened water have high sodium content,and their decontamination and cleaning abilities are significantly stronger than those of the purified water.Purified water has poorer effects in instruments cleaning for its deionized property.Using concentrated softened water or softened water in the surgical instrument cleaning process can achieve effects of reducing consumption and increasing efficiency,which is conducive to improving cleaning efficiency and quality.

Result Analysis
Print
Save
E-mail